Neurosense Therapeutics LTD

NeuroSense Therapeutics Ltd. CEO Alon Ben-Noon acquired 250,000 ordinary shares in a private placement.

NeuroSense Therapeutics Ltd. reports a significant share acquisition by its Chief Financial Officer, Or Eisenberg, through a private placement.

NeuroSense Therapeutics CFO Or Eisenberg received a grant of 200,000 restricted ordinary shares, increasing his beneficial ownership to 1,254,050 shares.

CTO Niva Russek-Blum received 200,000 restricted ordinary shares at $0, vesting quarterly over two years, bringing direct holdings to 467,953.

NeuroSense Therapeutics’ General Manager Hagit Binder reported a grant of 200,000 restricted ordinary shares at $0, vesting quarterly over two years.